Table 1. Patient characteristics (n 90).

	Wt KRAS (42 patients 47%)
Characteristics	No./total	%	Mt KRAS (48 patients, 53%)
Gender
M	26/42	62	30/48	62
F	16/42	38	18/48	38
Median age	64		62
Tumour site
Right colon	11/42	26	13/48	27
Trasversum	1/42	3	2/48	5
Descending colon	3/42	7	6/48	12
Sigmoid—rectum	27/42	64	27/48	56
Metastatic sites
Liver	35/42	83	38/48	80
Lung	17/42	40	21/48	44
Lymphonodes	5/42	12	8/48	17
Peritoneum	6/42	14	7/48	15
Other	4/42	10	2/48	4
FOLFOX
First line	22/42	52	27/48	56
Second line	20/42	48	21/48	44
PS (ECOG)
0	33/42	78	39/48	81
1	9/42	22	8/48	17
2	0/42	0	1/48	2
Synchronous metastases	34/42	80	36/48	75
Metachronuos metastases	8/42	20	12/48	25
Median time to relapse (m)	32		29
Surgery for primary tumour	39/42	93	44/48	91
Adjuvant CT (5-FU+folinic acid)	7/42	16	5/48	10
Third- and forth-line CT
Capecitabine	7/42	16	27/48	56
Anti-EGFR therapies	18/42	43	3/48	6
EGFR expression (68 patients; cutoff point 1%)
Overexpression	28/30	93	28/38	73
Underexpression	2/30	7	10/38	27

Abbreviations: CT=chemotherapy; ECOG=Eastern Cooperative Oncology Group; EGFR=epidermal growth factor receptor; F=female; FOLFOX=fluorouracil, leucovorin and oxaliplatin; FU=fluorouracil; M=male; Mt=muatted; PS=performance status; Wt=wild type.